glp-1 video Video: Non-insulin injectable antidiabetic drugs - agonists and amylinomimetics: Nursing pharmacology A 3d animation of pre-filled

No significant differences were demonstrated for GLP-1, GIP or glucagon z-scores in the group with metabolic syndrome compared to without metabolic syndrome

De Paoli, Monica, et al

Hence, these investigations illustrate that GLP-1R agonism effectively slows down the advancement of atherosclerosis through a glycemia-independent and endothelial GLP-1R-dependent pathway

Methodological limitations of existing research include: Observational study designs that cannot establish causationindividuals prescribed GLP-1 agonists may differ systematically from comparison groups Confounding variables such as concurrent lifestyle interventions, psychological support, or other medications Short follow-up periods that do not capture long-term outcomes or relapse patterns Publication bias , with positive findings more likely to be reported than null results Safety considerations are paramount

A crucial knowledge gap is the lack of head-to-head comparative studies evaluating their ocular effects